# Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab

> **NCT07363642** · PHASE3 · RECRUITING · sponsor: **AstraZeneca** · enrollment: 400 (estimated)

## Conditions studied

- Severe Asthma

## Interventions

- **DRUG:** Tezepelumab

## Key facts

- **NCT ID:** NCT07363642
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-28
- **Primary completion:** 2027-08-07
- **Final completion:** 2029-03-31
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2026-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07363642

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07363642, "Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07363642. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*